Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity.

Magee MS, Kraft CL, Abraham TS, Baybutt TR, Marszalowicz GP, Li P, Waldman SA, Snook AE.

Oncoimmunology. 2016 Sep 2;5(10):e1227897.

2.

The guanylate cyclase-C signaling pathway is down-regulated in inflammatory bowel disease.

Brenna Ø, Bruland T, Furnes MW, Granlund Av, Drozdov I, Emgård J, Brønstad G, Kidd M, Sandvik AK, Gustafsson BI.

Scand J Gastroenterol. 2015;50(10):1241-52. doi: 10.3109/00365521.2015.1038849.

3.

GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer.

Marszalowicz GP, Snook AE, Magee MS, Merlino D, Berman-Booty LD, Waldman SA.

Oncotarget. 2014 Oct 15;5(19):9460-71.

4.

Selective antigen-specific CD4(+) T-cell, but not CD8(+) T- or B-cell, tolerance corrupts cancer immunotherapy.

Snook AE, Magee MS, Schulz S, Waldman SA.

Eur J Immunol. 2014 Jul;44(7):1956-66. doi: 10.1002/eji.201444539.

5.

Tumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C.

Witek M, Blomain ES, Magee MS, Xiang B, Waldman SA, Snook AE.

Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):1188-95. doi: 10.1016/j.ijrobp.2013.12.043.

6.

The role of cyclic nucleotide signaling pathways in cancer: targets for prevention and treatment.

Fajardo AM, Piazza GA, Tinsley HN.

Cancers (Basel). 2014 Feb 26;6(1):436-58. doi: 10.3390/cancers6010436.

7.

Translating colorectal cancer prevention through the guanylyl cyclase C signaling axis.

Blomain ES, Lin JE, Kraft CL, Trela UT, Rock JM, Aing AS, Snook AE, Waldman SA.

Expert Rev Clin Pharmacol. 2013 Sep;6(5):557-64. doi: 10.1586/17512433.2013.827406. Review.

8.

Evidence-based Guidelines for Precision Risk Stratification-Based Screening (PRSBS) for Colorectal Cancer: Lessons learned from the US Armed Forces: Consensus and Future Directions.

Avital I, Langan RC, Summers TA, Steele SR, Waldman SA, Backman V, Yee J, Nissan A, Young P, Womeldorph C, Mancusco P, Mueller R, Noto K, Grundfest W, Bilchik AJ, Protic M, Daumer M, Eberhardt J, Man YG, Brücher BL, Stojadinovic A.

J Cancer. 2013;4(3):172-92. doi: 10.7150/jca.5834.

9.

Novel Therapeutics: NSAIDs, Derivatives, and Phosphodiesterases.

Tinsley HN, Piazza GA.

Curr Colorectal Cancer Rep. 2012 Dec;8(4):325-330.

10.

Guanylyl cyclase C as a biomarker in colorectal cancer.

Hyslop T, Waldman SA.

Biomark Med. 2013 Feb;7(1):159-67. doi: 10.2217/bmm.12.90. Review.

11.

Immunotherapeutic strategies to target prognostic and predictive markers of cancer.

Magee MS, Snook AE, Marszalowicz GP, Waldman SA.

Biomark Med. 2013 Feb;7(1):23-35. doi: 10.2217/bmm.12.110. Review.

12.

Evaluation of alpha 1-antitrypsin and the levels of mRNA expression of matrix metalloproteinase 7, urokinase type plasminogen activator receptor and COX-2 for the diagnosis of colorectal cancer.

Bujanda L, Sarasqueta C, Cosme A, Hijona E, Enríquez-Navascués JM, Placer C, Villarreal E, Herreros-Villanueva M, Giraldez MD, Gironella M, Balaguer F, Castells A.

PLoS One. 2013;8(1):e51810. doi: 10.1371/journal.pone.0051810.

13.

GUCY2C molecular staging personalizes colorectal cancer patient management.

Gong JP, Schulz S, Hyslop T, Waldman SA.

Biomark Med. 2012 Jun;6(3):339-48. doi: 10.2217/bmm.12.24. Review.

14.

Molecular staging individualizing cancer management.

Mejia A, Schulz S, Hyslop T, Weinberg DS, Waldman SA.

J Surg Oncol. 2012 Apr 1;105(5):468-74. doi: 10.1002/jso.21858. Review.

15.

Analytic lymph node number establishes staging accuracy by occult tumor burden in colorectal cancer.

Hyslop T, Weinberg DS, Schulz S, Barkun A, Waldman SA.

J Surg Oncol. 2012 Jul 1;106(1):24-30. doi: 10.1002/jso.23051.

16.

Cure and curse: E. coli heat-stable enterotoxin and its receptor guanylyl cyclase C.

Weiglmeier PR, Rösch P, Berkner H.

Toxins (Basel). 2010 Sep;2(9):2213-29. doi: 10.3390/toxins2092213. Review.

17.

Bacterial heat-stable enterotoxins: translation of pathogenic peptides into novel targeted diagnostics and therapeutics.

Lin JE, Valentino M, Marszalowicz G, Magee MS, Li P, Snook AE, Stoecker BA, Chang C, Waldman SA.

Toxins (Basel). 2010 Aug;2(8):2028-54. doi: 10.3390/toxins2082028. Review.

18.

Occult tumor burden contributes to racial disparities in stage-specific colorectal cancer outcomes.

Hyslop T, Weinberg DS, Schulz S, Barkun A, Waldman SA.

Cancer. 2012 May 1;118(9):2532-40. doi: 10.1002/cncr.26516.

19.

Occult tumor burden predicts disease recurrence in lymph node-negative colorectal cancer.

Hyslop T, Weinberg DS, Schulz S, Barkun A, Waldman SA.

Clin Cancer Res. 2011 May 15;17(10):3293-303. doi: 10.1158/1078-0432.CCR-10-3113.

20.

Sex modulates intestinal transformation by the tumor-suppressor GCC.

Li P, Schulz S, Pitari GM, Waldman SA.

Clin Transl Sci. 2008 Sep;1(2):150. doi: 10.1111/j.1752-8062.2008.00010.x. No abstract available.

Supplemental Content

Support Center